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twelve physicians. A mapping instrument was developed to allo-
cate values of HRQL impact to ﬁfty chemotherapy-related AEs.
The HRQL impact was measured on a ﬁve-point scale for direct
comparison with the CTC. RESULTS: This analysis revealed that
approximately half (23 of 50) of the AEs had HRQL impact
values that were different to their CTC grades. For the majority
(17 of 23), the HRQL impact value was lower than the CTC
grade. The results of the HRQL impact survey conﬁrmed that
the CTC classiﬁcation does not always reﬂect the impact on
patient HRQL and that in general, low to moderate grade
leukopenic and thrombocytopenic haematological events have
lower impact on patient HRQL than non-haematological events.
Vomiting, pain, sensory neuropathy, rigors, chills and fever had
a higher impact on HRQL than the CTC would suggest. CON-
CLUSIONS: We have proposed a method for estimation of the
HRQL impact of AEs on chemotherapy patients that has face
validity. This research provides a basis to quantify the HRQL
impact of chemotherapy-related AEs. This could then be used to
assess the value of various chemotherapy agents in cost-utility
analyses.
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OBJECTIVE: To develop a short new scale to assess patient per-
ceptions of cancer-related fatigue (CRF), and determine the
beliefs and expectations of cancer patients with CRF.
METHODS: To deﬁne the ﬁrst version of the questionnaire a
two-phase methodology was used. Firstly, initial item content
was deﬁned by integrating information from: 1) a literature
review performed to identify related studies; 2) content analysis
of two focus groups carried out with cancer patients; and 3) two
expert meetings with oncologists. To reduce the item pool and
produce the ﬁrst version of the questionnaire for validation, a
multicentre cross-sectional study was performed and the item
pool was administered to a sample of the target population. Item
reduction was based on a clinimetric approach, so that for each
item in the initial pool, frequency and importance were assessed
by a Likert scale and the frequency and importance product
index (PI) was calculated. Item selection was based on the order-
ing of items based on the PI. RESULTS: The initial item pool
included 75 double-items referring to mental attitude (7), social
and family (15), psychological impact (12), physical functioning
(12), daily life activities (12) and general opinions (17). Initial
pool was administered to 238 cancer patients: mean age 57, 56%
women, 30% breast cancer, 46% with anemia, average of low-
to-moderate CRF intensity. 95% of sample responded at least
85% of items. Average of missing items per patient was 4.5. PI
ranged from 4.9 to 12.4 and the ﬁrst 40 items were selected and
preliminarily assigned to six dimensions (physical, social, psy-
chological, attitudes, daily life activities, opinions). CONCLU-
SION: Preliminary results from the item reduction process have
led to a ﬁrst version of the questionnaire with 40 items and six
dimensions. The next stage will examine the psychometric prop-
erties of the new measure in a larger sample.
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OBJECTIVES: To establish whether a standard questionnaire
exists for evaluating quality of life (QoL) in patients with mCRC.
METHODS: We conducted a search of the published literature
on QoL, chemotherapy, and colorectal cancer between 1998 and
2004, excluding studies with limited total sample sizes (<50). We
reviewed twenty studies with unique patient populations cover-
ing nine QoL questionnaires and nine chemotherapy drugs.
RESULTS: Most studies were conducted in Europe (primarily the
UK), average sample size was 184 patients per study arm (range:
25, 411). The EORTC QLQ-C30 was the most commonly used
questionnaire (17 studies). Generally, it was administered in
treatment trials starting at baseline and every 6 weeks thereafter
until disease progression (on average 2 years duration). Few
EORTC QLQ-C30 studies (2 of 15 multi-arm studies) were able
to detect differences between groups other than on the diarrhea
item. Recently, two supplemental CRC speciﬁc modules were
developed, the EORTC QLQ-CR38 and FACT-C. While the
EORTC QLQ-CR38 module focuses more on symptoms, the
FACT-C considers patients’ attitudes towards their cancer. One
study used the EORTC QLQ-CR38 and was able to detect treat-
ment group differences in symptoms; speciﬁcally, stoma-related,
micturition, defecation, and sexual problems, gastrointestinal
tract symptoms, body image, and future perspective. Another
study used the FACT-C along with other FACT speciﬁc modules
to compare QoL across different cancer types. Minimal differ-
ences (due to the small sample size in each cancer type) were
observed. CONCLUSIONS: The EORTC QLQ-C30 is the most
commonly used questionnaire in mCRC patients receiving
chemotherapy. With increased use and availability of transla-
tions, the EORTC QLQ-CR38 and FACT-C will likely prove to
be more sensitive in detecting differences. Common patterns
exist for the administration (coinciding with cycles) and dura-
tion of follow-up (≥1 year), yet no standard QoL questionnaire
emerged able to detect group differences for mCRC patients
receiving chemotherapy.
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OBJECTIVE: Patient Satisfaction and Quality in Oncological
Care (PASQOC®) 2002 was the ﬁrst assessment in Germany
focusing on patient satisfaction in oncology. In 2004 PASQOC®
was rerun to assess and observe quality of oncological care over
time (2002/2004). Of 49 participating practices and ambulances,
16 were following-up on their 2002 experience. METHODS: All
cancer patients presenting at the investigators’ practices within
a deﬁned recruiting period received the validated questionnaire
PASQOC® via mail. Patients’ inclusion criteria: German speak-
ing, ≥18 years, conﬁrmed cancer diagnosis, physical/mental
ability to complete self-administered questionnaire. Analysis
based on dichotomous “problem scores” indicating the presence
or absence of a problem. These are summed into 13 “dimension
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scores”, each clustering a deﬁned set of questions. RESULTS:
(2002 ﬁgures in brackets): Samples did not differ signiﬁcantly in
structure. The 16 practices recruited n = 1639 patients (n =
1826), 50.9% women (55.0); mean age 63.6 years (62.4). Com-
paring 2004 with 2002 it is demonstrated that 5 practices
showed overall improvement in all dimensions, 3 practices
improved in some, 4 practices improved and decreased, while 4
maintained steady state. Patients of one practice reported much
more problems in all dimensions in 2002 than on average. In
2004, the practice presents with only “praxis organisation”
being still an issue for patients (+37%). This practice demon-
strated an overall better performance based on improvements in
8 out of 13 scales. Problem scores dropped (i.e. improvement)
especially interpersonal communication dimensions, i.e. patient-
physician relationship (-56%), co-management (-32%),
involvement of family members (-54%), discussion with other
patients (-41%). CONCLUSION: Assessing patient satisfaction
over time is one tool to generate a platform for quality assur-
ance in oncological care. The PASCOQ® questionnaire is a tool
to assess not only status quo but is also feasible to detect changes
in patients’ satisfaction with physicians, staff, environment as
well as side effects and supportive medication.
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OBJECTIVES: To assess the estimated prevalence of possible
ﬁbromyalgia sufferers among the general adults population in
Portugal using a screening questionnaire, the LFES-SQ developed
by White. METHODS: This questionnaire was administrated to
a random community sample of 500 persons interviewed by tele-
phone and positive responders to the screening questionnaire
were classiﬁed as “pain sufferers”. Using a sample of patients
coming to Rheumatologist departments we administrated to
them the same screening questionnaire and we diagnosed this
entire sample to see if they were ﬁbromyalgia sufferers (using the
1990 ACR criteria). Once we had calculated the ratio between
patients “positive” to the screening questionnaire and the
number of patients really diagnosed with ﬁbromyalgia, we
applied this ratio to our population of “pain sufferers” and
therefore obtain an estimate of the prevalence of possible
ﬁbromyalgia sufferers. It is important to note that we worked 
on two different populations. RESULTS: In Portugal following
the hospital survey the results were the following: 225 inter-
viewed patients (191 women, 34 men) among them 154 were
screened positive (136 and 18) and 51 cases of ﬁbromyalgia (50
and 1) therefore multiplication factors of possible ﬁbromyalgia
patients VS number of positive = Total ﬁbromyalgia cases in
Lisboa / Number of Patients screened positive i.e. . . . multipli-
cation factor for the total population = 51/154 = 0.331; for
women = 50/136 = 0.368 and for men = 1/18 = 0.056. Once
those ratio were applied to our random community representa-
tive sample of 500 persons we obtained the following: an esti-
mated prevalence of FMS in Portugal of 6.09% of the total
population, 8.76% of women and 0.69% of men. CONCLU-
SION: Those data are higher than the ones obtained in the White
study or in the published prevalence of ﬁbromyalgia in the liter-
ature, but they allow us to assess an estimated prevalence of
ﬁbromyalgia.
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OBJECTIVE: To assess the estimated prevalence of possible
Fibromyalgia (FM) sufferers among the general adults popula-
tion in Italy using the LFES-SQ, a screening questionnaire 
developed by White. METHODS: This questionnaire was
administrated to a random community sample of 1000 persons
interviewed by telephone and positive responders to the screen-
ing questionnaire were classiﬁed as “pain sufferers”. Using a
ratio calculated in Portugal between patients “positive” (+) to
the screening questionnaire and the number of patients really
diagnosed with FMS, we applied this ratio to our population of
“pain sufferers” and therefore obtain an estimate of the preva-
lence of possible ﬁbromyalgia sufferers in Italy, please note that
we worked on two different populations. The ratio was calcu-
lated using a sample of patients in Lisboa, to whom we admin-
istrated the same screening questionnaire and we diagnosed this
entire sample to see if they were FMS sufferers (using the 1990
ACR criteria). RESULTS: In Portugal following the hospital
survey we were able to calculate the following ratios: Multipli-
cation factors of possible FMS patients VS number of (+) = Total
FM cases in Lisboa / Number of Patients screened (+), i.e. . . .
multiplication factor for the total population = 51/154 = 0.331;
multiplication factor for women = 50/136 = 0.368; multiplica-
tion factor for men = 1/18 = 0.056. Once those ratio were applied
to our random sample of 1000 persons we obtained an estimated
prevalence of FMS in Italy of 4.17% of the total population,
6.99% of women and 0.31% of men. CONCLUSION: Those
data are higher than those obtained in the White study or in the
published prevalence of FMS in the literature, but they allow us
to assess an estimated prevalence of FMS. The next steps will be
to calculate local multiplication factors of FMS in Italy in order
to improve those estimates and to generalise this survey in
Europe.
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OBJECTIVE: To compare the management of ﬁbromyalgia
amongst French and Portuguese General Practitioners (GPs).
METHODS: A questionnaire with a prepaid envelope was sent
to a sample of 10,000 GPs in France and to all practicing GPs
(n = 8399) in Portugal. This questionnaire was organized in six
main sections: the characteristics of the physician’s professional
practice, the physician’s opinion on ﬁbromyalgia, the main symp-
toms of ﬁbromyalgia, diagnosis criteria, treatments of ﬁbromyal-
gia, sources of knowledge on ﬁbromyalgia. RESULTS: A total of
1130 French GPs (response rate: 11.3%) and 337 Portuguese
GPs (response rate: 4%) returned the questionnaire. In France
66% are male with an average age of 47, whereas in Portugal
52% are male with an average age of 50. The proﬁle of the
respondents is similar in age and gender to the average national
proﬁle. Thirty-three percent of French GPs and 29.5% of the
Portuguese ones afﬁrm that ﬁbromyalgia is a disease; 63% and
68% respectively claim it is a symptom and it is only for 2% of
French and 2.5% of the Portuguese GPs that ﬁbromyalgia does
